ROCK & ASSOCIATES for PRECISION PHARMACY
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Aug 1, 2020 | $11,250 | Replaced |
| 2nd Quarter - Amendment (this page) | Aug 26, 2020 | $11,250 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Budget/Appropriations BUD
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Pharmacy PHA
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES W ROCK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.